PMID- 24647152
OWN - NLM
STAT- MEDLINE
DCOM- 20140814
LR  - 20191112
IS  - 1881-7831 (Print)
IS  - 1881-7831 (Linking)
VI  - 8
IP  - 1
DP  - 2014 Feb
TI  - Pharmacological effects and clinical applications of ultra low molecular weight 
      heparins.
PG  - 1-10
AB  - Heparin, one of the common anticoagulants, is clinically used to prevent and 
      treat venous thromboembolism (VTE). Though it has been the drug of choice for 
      many advanced medical and surgical procedures with a long history, the adverse 
      events, such as bleeding, heparin-induced thrombocytopenia (HIT), allergic 
      reactions, follow. Therefore, low molecular weight heparins (LMWHs) and ultra low 
      molecular weight heparins (ULMWHs), with lower molecular weights, higher anti-FXa 
      activity, longer half-life times and lower incidence of adverse events than 
      unfractionated heparin (UFH), were researched and developed. Fondaparinux, a 
      chemically synthesized ULMWH of pentasaccharide, has the same antithrombin III 
      (AT-III)-binding sequence as found in UFH and LMWH. In addition, AVE5026 and 
      RO-14, another two ULMWHs, are obtained by selective chemical depolymerization. 
      In this paper, we review the preparation process, pharmacological effects and 
      clinical applications of fondaparinux, AVE5026 and RO-14.
FAU - Liu, Zhang
AU  - Liu Z
AD  - Key Laboratory of Chemical Biology of Natural Products (Ministry of Education), 
      Institute of Biochemical and Biotechnological Drug, School of Pharmaceutical 
      Sciences, Shandong University.
FAU - Ji, Shengli
AU  - Ji S
FAU - Sheng, Juzheng
AU  - Sheng J
FAU - Wang, Fengshan
AU  - Wang F
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Japan
TA  - Drug Discov Ther
JT  - Drug discoveries & therapeutics
JID - 101493809
RN  - 0 (AVE 5026)
RN  - 0 (Anticoagulants)
RN  - 0 (Factor Xa Inhibitors)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 0 (Polysaccharides)
RN  - 9005-49-6 (Heparin)
RN  - EC 3.4.21.6 (Factor Xa)
RN  - J177FOW5JL (Fondaparinux)
SB  - IM
MH  - Animals
MH  - Anticoagulants/adverse effects/chemical synthesis/pharmacokinetics/*therapeutic 
      use
MH  - Blood Coagulation/drug effects
MH  - *Drug Design
MH  - Factor Xa/metabolism
MH  - Factor Xa Inhibitors
MH  - Fondaparinux
MH  - Half-Life
MH  - Hemorrhage/chemically induced
MH  - Heparin/analogs & derivatives/therapeutic use
MH  - Heparin, Low-Molecular-Weight/adverse effects/chemical 
      synthesis/pharmacokinetics/*therapeutic use
MH  - Humans
MH  - Molecular Structure
MH  - Molecular Weight
MH  - Polysaccharides/therapeutic use
MH  - Structure-Activity Relationship
MH  - Venous Thromboembolism/*drug therapy
EDAT- 2014/03/22 06:00
MHDA- 2014/08/15 06:00
CRDT- 2014/03/21 06:00
PHST- 2014/03/21 06:00 [entrez]
PHST- 2014/03/22 06:00 [pubmed]
PHST- 2014/08/15 06:00 [medline]
AID - DN/JST.JSTAGE/ddt/8.1 [pii]
AID - 10.5582/ddt.8.1 [doi]
PST - ppublish
SO  - Drug Discov Ther. 2014 Feb;8(1):1-10. doi: 10.5582/ddt.8.1.